Threshold Pharmaceuticals
Threshold Pharmaceuticals Newswire

Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 59 in Threshold Pharmaceuticals

  1. Short Interest in Threshold Pharmaceuticals, Inc. (THLD) Increases By 40.8%Read the original story w/Photo

    Sunday Jan 31 | AmericanBankingNews.com

    Threshold Pharmaceuticals, Inc. saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 2,169,360 shares, a growth of 40.8% from the December 31st total of 1,540,359 shares, MarketBeat.com reports.

    Comment?

  2. Threshold Pharmaceuticals gets Nasdaq delisting warningRead the original story w/Photo

    Friday Jan 22 | Seeking Alpha

    In a filing, Threshold Pharmaceuticals says it's gotten a delisting warning from Nasdaq after 30 straight business days below the $1 minimum bid price. The company will have until July 19 to regain compliance with that rule, by lifting its minimum bid price over $1.00 for 10 straight business days at any time.

    Comment?

  3. Threshold Pharma And Merck KGaA, Darmstadt, Germany Agree To Key...Read the original story

    Jan 11, 2016 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced an update on its evofosfamide program including that Threshold and Merck KGaA, Darmstadt, Germany have agreed upon key terms for the licensing back of all rights to evofosfamide to Threshold. The companies have a global license and co-development agreement for evofosfamide, an investigational hypoxia-activated prodrug for the treatment of cancer, which was discovered and initially developed by Threshold.

    Comment?

  4. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Receives Consensus...Read the original story w/Photo

    Dec 30, 2015 | AmericanBankingNews.com

    Shares of Threshold Pharmaceuticals, Inc. have been given a consensus recommendation of "Buy" by the six ratings firms that are presently covering the stock, MarketBeat.Com reports . Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company.

    Comment?

  5. Bay Area Threshold Pharma Slashes Two Thirds of WorkforceRead the original story

    Dec 20, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that it has initiated a significant reduction in its workforce in order to focus the company's financial resources in the near term on two ongoing Phase 2 proof-of-concept clinical trials of tarloxotinib bromide* , the company's novel epidermal growth factor receptor tyrosine kinase inhibitor licensed from the University of Auckland, New Zealand. Threshold will reduce its workforce by approximately two-thirds, resulting in between 20-25 remaining employees.

    Comment?

  6. Threshold Pharmaceuticals Announces Workforce ReductionRead the original story

    Dec 18, 2015 | Sys-Con Media

    12/18/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it has initiated a significant reduction in its workforce in order to focus the company's financial resources in the near term on two ongoing Phase 2 proof-of-concept ...

    Comment?

  7. Sarcoma Field Digests Evofosfamide FailureRead the original story w/Photo

    Dec 10, 2015 | Seeking Alpha

    The failure of the phase III study of evofosfamide in soft tissue sarcoma which was itself only half of an unprecedented double dose of disappointment meted out to Threshold Pharmaceuticals yesterday has left observers pondering the implications for future development in this cancer field. Most obviously, Threshold's discontinuation of evofosfamide leaves an already thin pipeline in this indication even thinner .

    Comment?

  8. Threshold Pharma Announces Its Two Phase 3 Studies Evaluating...Read the original story

    Dec 7, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced the outcomes of two Phase 3 cancer studies of evofosfamide , an investigational hypoxia-activated prodrug, which is being evaluated for first-line treatment of advanced pancreatic adenocarcinoma and advanced soft tissue sarcoma, in combination with chemotherapy. The Phase 3 studies are being conducted under Threshold's collaboration with Merck KGaA, Darmstadt, Germany.

    Comment?

  9. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Given Average Recommendation of "Buy" by BrokeragesRead the original story w/Photo

    Dec 7, 2015 | AmericanBankingNews.com

    Shares of Threshold Pharmaceuticals, Inc. have been assigned a consensus recommendation of "Buy" from the six research firms that are presently covering the company, Marketbeat.com reports . Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company.

    Comment?

  10. Threshold Pharmaceuticals, Inc. (THLD) Stock Rating Lowered by Piper JaffrayRead the original story w/Photo

    Dec 7, 2015 | AmericanBankingNews.com

    A number of other research analysts have also recently commented on THLD. RBC Capital reiterated a "buy" rating on shares of Threshold Pharmaceuticals in a research note on Tuesday, September 15th.

    Comment?

  11. Threshold Pharmaceuticals, Inc. (THLD) Downgraded by Cowen and Company to "Market Perform"Read the original story w/Photo

    Dec 7, 2015 | AmericanBankingNews.com

    THLD has been the topic of a number of other reports. Stifel Nicolaus lowered shares of Threshold Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday.

    Comment?

  12. Threshold Pharmaceuticals, Inc. (THLD) Rating Lowered to Hold at Stifel NicolausRead the original story w/Photo

    Dec 7, 2015 | AmericanBankingNews.com

    Threshold Pharmaceuticals opened at 3.34 on Monday. The firm's 50-day moving average is $3.95 and its 200-day moving average is $4.12.

    Comment?

  13. Threshold Pharma Crumbles as Merck KGaA Abandons Cancer Drug After Trial FailuresRead the original story

    Dec 6, 2015 | BioSpace

    Despite signs of activity in locally advanced and metastatic pancreatic cancer, two Phase III studies did not meet pre-specified primary endpoints , a leading science and technology company, today announced that it is not planning to file for approval of evofosfamide in advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma. The decision was made in light of results from two Phase III studies of evofosfamide in combination with chemotherapy in these two types of cancer, as reported by Threshold Pharmaceuticals Inc. today.

    Comment?

  14. UPDATE 1-Merck KGaA, Threshold drug fails in late-stage cancer trialsRead the original story

    Dec 7, 2015 | Reuters

    FRANKFURT, Dec 7 Germany's Merck KGaA and development partner Threshold Pharmaceuticals said their experimental cancer drug evofosfamide failed to extend lives in two late-stage clinical studies, a major setback for both firms. Evofosfamide did not meet the main goal of improving survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against these cancer forms.

    Comment?

  15. German stocks - Factors to watch on December 7Read the original story

    Dec 6, 2015 | Reuters

    ... exit door, a spokesman for the German carrier said. Germany's Merck KGaA and development partner Threshold Pharmaceuticals said their experimental cancer drug evofosfamide failed to show the desired effects in two late stage studies. The carmaker ...

    Comment?

  16. Threshold Pharmaceuticals Announces Its Two Phase 3 Studies...Read the original story

    Dec 6, 2015 | Sys-Con Media

    12/07/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the outcomes of two Phase 3 cancer studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, which is ...

    Comment?

  17. Threshold Pharmaceuticals: Let's Let The Data Do The TalkingRead the original story w/Photo

    Dec 4, 2015 | Seeking Alpha

    THLD has a promising, clever drug in two phase 3 clinical trials: one for pancreatic cancer and one for soft tissue sarcomas. As of September 2015 , THLD has about $55 million cash and marketable securities.

    Comment?

  18. A Rebuttal To The Bear Case On Anavex's 3-71Read the original story w/Photo

    Dec 3, 2015 | Seeking Alpha

    ... most recent article regarding Anavex (NASDAQ: AVXL ), Northwest Biotherapeutics (NASDAQ: NWBO ), Threshold Pharmaceuticals (NASDAQ: THLD ), and Biomarin (NASDAQ: BMRN ), it appears he needlessly goes for the throat, and presents some scientific as ...

    Comment?

  19. Threshold Pharma Enters Into Definitive Co-Promotion Agreement For...Read the original story

    Nov 18, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck KGaA, Darmstadt, Germany pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide in the U.S. subject to Food and Drug Administration approval of evofosfamide.

    Comment?

  20. Brokerages Anticipate Threshold Pharmaceuticals to PostRead the original story

    Nov 18, 2015 | AmericanBankingNews.com

    Threshold Pharmaceuticals has been given a consensus broker rating score of 1.00 from the seven brokers that provide coverage for the stock, Zacks Investment Research reports. Seven research analysts have rated the stock with a strong buy recommendation.

    Comment?